Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL812682 | 0.85 | PKM (0.79) | ESR1PKMALDH1A1CA12CA9 | |
| SCHEMBL7811989 | 0.81 | CA12 (0.71) | ESR1ALDH1A1CA12CA9NPC1 | |
| SCHEMBL3697451 | 0.80 | PKM (0.71) | ESR1PKMALDH1A1CA12CA9 | |
| SCHEMBL8976129 | 0.80 | PKM (0.71) | ESR1PKMALDH1A1CA12CA9 | |
| SCHEMBL9078050 | 0.78 | ESR1 (0.63) | ESR1PKMESR2CA12CA9 | |
| SCHEMBL10904389 | 0.77 | ESR1 (1.00) | ESR1ALDH1A1 | |
| SCHEMBL6678557 | 0.76 | PKM (0.66) | ESR1PKMALDH1A1CA12CA9 | |
| SCHEMBL21746060 | 0.76 | PKM (0.65) | ESR1PKMALDH1A1CA12CA9 | |
| SCHEMBL21745763 | 0.76 | PKM (0.65) | ESR1PKMALDH1A1CA12CA9 | |
| SCHEMBL3258764 | 0.76 | ESR1 (0.61) | ESR1PKMALDH1A1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | claimed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | claimed |
| WO-2008130571-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-10-30 | — | — | WO | claimed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | claimed |
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | disclosed |
| US-8637706-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120157539-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2012-06-21 | — | — | US | disclosed |
| EP-2455362-A1 | Nuclear receptor binding agents | GTX, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| US-8158828-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090062341-A1 | Nuclear receptor binding agents | GTX, INC | 2009-03-05 | — | — | US | disclosed |
| WO-2008130571-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | ESRRB, ESRRA, ESR2 | ESR1 7/4885PKM 4377/4885ALDH1A1 2700/4885 |
| US-20070265296-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | ESR1 5/4885PKM 1725/4885ALDH1A1 3644/4885 |
| US-20090062341-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | ESR1 5/4885PKM 1725/4885ALDH1A1 3644/4885 |
| US-20120157539-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GPER1, ESRRG, ESR2 | ESR1 5/4885PKM 1725/4885ALDH1A1 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.